Read Why Mizuho Is Bullish On Kraft Heinz
Mizuho analyst John Baumgartner initiated coverage of Kraft Heinz Co (NASDAQ:KHC) with a Buy rating and a price target of $48, implying…
AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022
Genmab A/S (NASDAQ:GMAB) has announced that AbbVie Inc (NASDAQ:ABBV) will submit a conditional marketing authorization application with the European Medicines Agency…
Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
Algernon Pharmaceuticals Inc (OTC:AGNPF) has announced topline data showing that it has met the co-primary endpoint in its Phase 2 proof…
PMV Pharma, Merck Ink Clinical Trial Collaboration For Combination Study In Solid Tumors
PMV Pharmaceuticals Inc (NASDAQ:PMVP) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK) to evaluate PC14586…
This Day In Market History: The Founding Of Intel
Each day, Benzinga takes a look back at a notable market-related moment that occurred on this date.
What Happened?
On this day 51 years ago, Intel Corporation (NASDAQ: INTC) was founded.
Apyx Medical’s Renuvion Scores FDA Approval To Eliminate Sagging Neck
The FDA has granted 510(k) clearance for Apyx Medical Corporation’s (NASDAQ:APYX) Renuvion for subcutaneous dermatological and aesthetic procedures to improve the appearance…
3 Financial Players To Watch In Cannabis: Alternative Funding Options For A Burgeoning Industry
Opening a small or medium-sized cannabis business requires capital. While federal legalization of marijuana is inching closer to reality, banks are finding it difficult to keep up with regulations within different states that are constantly changing.
‘New data might have led to a different result for Amarin fish oil drug, FDA panelists say’ -STAT News
https://www.statnews.com/2022/07/18/new-data-might-have-led-to-a-different-result-for-amarin-fish-oil-drug-fda-panelists-say/
Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO
Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ:ENTX) has designed the pivotal study for EB613 as…